Similarly, the growing proportion of older individuals in economically developed and developing nations, and the propensity to develop chronic pain-producing conditions with advancing age (e.g. osteoarthritis, degenerative spine disease, vasculopathy, diabetes mellitus, and cancer), is leading to a high prevalence of chronic pain worldwide. Unfortunately, currently available analgesic medications and pain-modulating procedures are severely limited by combinations of low efficacy, excessive toxicity/risk/safety concerns, insufficient access to care, or unbearable cost. In patients with chronic Inhibitors,research,lifescience,medical pain, and especially neuropathic

pain, “success” is measured in small increments of improvement among limited numbers of patients. In randomized clinical trials Inhibitors,research,lifescience,medical of analgesics for neuropathic pain, no more than half of patients experience clinically meaningful pain relief from pharmacotherapy.3 More effective and universally available means to Inhibitors,research,lifescience,medical prevent and treat chronic pain are needed, regardless of

the primary or inciting cause. Against this background of extraordinary need, this paper will provide an overview of the developing basic and clinical science of cannabinoid pharmacology, and the potential therapeutic value of cannabinoids Inhibitors,research,lifescience,medical for chronic pain management.4,5 The first portion of this article presents a very basic review of the pharmacology of

the cannabinoids and endocannabinoid receptor system, drawing both from animal and human models.6 Although cannabinoids have putative therapeutic effects in a wide variety of clinical conditions, some of Inhibitors,research,lifescience,medical which (e.g. diabetes) are associated with chronic painful conditions, the focus herein is on the effect of cannabinoids on pain rather than on other pathophysiological states. This introduction will pave the way to insight and understanding of the potential role of this class of agents in pain control. Other than to understand basic mechanisms and to formulate hypotheses of safety and efficacy, experience has shown us that animal or human experimental pain investigations poorly predict responses to analgesic therapies in “real life” situations. From this perspective, the second part of this Dichloromethane dehalogenase review focuses on pain relief in the clinical setting, and only the human experience will be described. Extensive research and prolonged exposure to cannabinoids both in animals and humans have addressed important questions about safety. Cannabinoids have a very high therapeutic index. In fact, it is virtually unlimited insofar as P450 inhibitor fatalities have not been reported directly related to the toxicity of any cannabinoid, even with extremely high dosing.